Ann: Q1 2024 Investor Webinar Presentation, page-8

any material news requires an asx release. There is never any new news in these things, but sometimes you find out a bit more nitty gritty. Like the RP11 3rd dose cohort hasn’t yet happened to all 3 and it was meant to be by Xmas, so now thats about a 4-6 week delay. Unfortunately every delay in a given program just adds to the time til efficacy gets proven or revenue gets banked. . There doesn’t tend to be any ‘slack” built in to stated timelines as a rule.
Having said that, each program is not dependent on the other so there is progress towards the mother of all drugs PKD and a significant rate and the biomarker readouts in second half of next year will be the turning point in my view. I actually dont see why we could get 1 or 2 readouts in the first half of next year to tease us, although statistically that will be meaningless….but if it works well they could report it. Other stiff will drop in April may so that should see a build of of buying in march and it is already feb.
So we should get back above 10c pretty soon and stay there in my view.